Navigation Links
Novel radiotracer shines new light on the brains of Alzheimer's disease patients
Date:6/24/2010

A trial of a novel radioactive compound readily and safely distinguished the brains of Alzheimer's disease patients from healthy volunteers on brain scans and opens the doors to making such imaging available beyond facilities that can manufacture their own radioactive compounds. The results, reported by a Johns Hopkins team in the June Journal of Nuclear Medicine, could lead to better ways to distinguish Alzheimer's from other types of dementia, track disease progression and develop new therapeutics to fight the memory-ravaging disease.

Previously, the only way to peer into the brains of Alzheimer's patients was through autopsy or the use of another radioactive compound used in scans, or radiotracer, known as Pittsburgh compound or PIB. PIB is drawn to a protein known as beta-amyloid, which accumulates abnormally in the brains of Alzheimer's patients. However, PIB has a half-life of only 20 minutes, meaning that half of the substance degenerates every 20 minutes after it is made. Consequently, PIB's use is possible only at a few hospitals or academic medical centers with facilities to manufacture it since this compound degenerates so rapidly.

To solve this conundrum, Dean F. Wong, M.D., Ph.D., a professor of radiology and psychiatry at the Johns Hopkins University School of Medicine, and his colleagues looked to a new radiotracer known as 18F-AV-45 (also known as florbetapir F18). This compound, based on the radioactive isotope fluorine-18, is drawn to beta-amyloid like PIB. However, unlike PIB, florbetapir has a half-life of about 110 minutes, greatly increasing its ability to be transported significant distances away from manufacturing facilities.

Testing the new compound for the first time in humans, Wong and his colleagues recruited 26 volunteers 11 previously diagnosed with Alzheimer's disease, and 15 healthy subjects of similar age who performed normally on cognitive tests. Each of these volunteers received an injection of florbetapir, then received a PET scan of their brains. The brain scans, acquired over a 90-minute period, allowed the researchers to see the uptake of florbetapir in the brain over time.

Florbetapir had significantly heavier accumulation in the Alzheimer's patients' brains compared to the healthy volunteers, collecting in brain regions expected to be high in beta-amyloid deposits based on previous research. The results in AD patients were readily distinguishable from those of healthy subjects by 30 minutes after injection, and the differences continued for up to at least 90 minutes after injection of florbetapir. None of the AD patients or healthy volunteers suffered any ill effects from florbetapir and showed normal vital signs, electrocardiograms and blood-work after the scan.

"We could easily tell apart the two groups of patients. Those without Alzheimer's disease retained much less of the compound, and those with Alzheimer's disease retained much more of it," Wong says. "This is the first time we've been able to get results like this with a compound that can travel beyond the confines of a major academic medical center to the majority of the U.S. population."

Wong adds that florbetapir's portability could lead to numerous applications for this compound. For example, though Alzheimer's disease can usually be diagnosed from neurocognitive tests, imaging with florbetapir could help settle tricky cases in which patients might have other forms of dementia instead. The compound may also be useful in future studies designed to help solve current medical mysteries, such as which patients are most likely to progress from mild cognitive impairment to full-blown Alzheimer's disease.

Florbetapir may also be useful in trials of new experimental Alzheimer's therapeutics to measure their success, a purpose for which this compound is already being used on a limited basis, Wong says.


'/>"/>

Contact: Christen Brownlee
cbrownlee@jhmi.edu
410-955-7832
Johns Hopkins Medical Institutions
Source:Eurekalert

Related medicine news :

1. Team led by LA BioMed scientist develops novel approach to study neurological disorders
2. Novel paclitaxel formulation encouraging for treating advanced lung cancer
3. Novel Drug Combats Advanced Melanoma
4. Novel RNA interference screening technique identifies possible path for malignant glioma treatment
5. Novel anti-malarial drug candidate found by UT Southwestern researchers
6. ASCO data highlight novel anti-cancer approach that exposes tumors to immune attack
7. Research identifies patterns of CD24, a novel biomarker for non-small cell lung carcinomas
8. Third European Novel Food Approval Received by Tahitian Noni International
9. Novel nanoparticles prevent radiation damage
10. Novel soy germ-based dietary supplement, SE5-OH containing natural S-Equol, examined for safety and influence on hormones in pre- and post-menopausal women
11. Novel Method Eyed for Normalizing Blood Sugar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... , ... January 24, 2017 , ... A fifth-year speaker ... of Cypress Benefit Administrators, will return to present about the state of the Affordable ... a “Benefits Adventure” theme this year – will be hosted at Disney’s Grand Californian ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... the expansion of its Medication Counseling Centers to address market needs. To support ... MCC staff by more than 60 percent over the past 6 months. The ...
(Date:1/24/2017)... New York, New York (PRWEB) , ... January 24, 2017 , ... ... demand for Brazilian butt lifts is on the rise. According to the American ... buttock augmentations since 2000. On average, these procedures are performed every 30 minutes of ...
(Date:1/24/2017)... Bethesda, MD (PRWEB) , ... January 24, 2017 ... ... Medical Informatics Association (AMIA) commended the Patient-Centered Outcomes Research Institute (PCORI) for developing ... informaticians suggested that PCORI consider requiring a preliminary data sharing plan as part ...
(Date:1/24/2017)... ... January 24, 2017 , ... To answer the growing demand ... Companies, has designated The Deco a 55 and over residence. ... older in no less than 80% of occupied units. The Deco’s 114 apartments are ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... , Jan. 24, 2017 A coalition ... International Development (USAID), the W.K. Kellogg Foundation and ... the Saint Boniface Haiti Foundation (SBHF) last week ... Port-au-Prince . The partnership provides ... Pou Amelyore Ekipman Medikal (REPARE) program, enabling the ...
(Date:1/24/2017)... , Jan. 24, 2017 Italy Ultrasound Systems Market ... ... Market Outlook to 2022", provides key market data on the ... of US dollars, volume (in units) and average prices (USD) ... Real-Time 3D/4D Ultrasound Systems and Hand Held Ultrasound (HHU) Systems. ...
(Date:1/24/2017)... 24, 2017 Asia-Pacific Bone Densitometers Market ... report, "Asia-Pacific Bone Densitometers Market Outlook to 2022", ... Densitometers market. The report provides value, in millions ... prices (USD) within market segements - Dual Energy ... The report also provides company shares and distribution ...
Breaking Medicine Technology: